|
|
 Previous Article | Table of Contents | Next Article 
In vivo effects of recombinant human interleukin-6 in primates: stimulated
production of platelets
S Asano, A Okano, K Ozawa, T Nakahata, T Ishibashi, K Koike, H Kimura, Y Tanioka, A Shibuya and T Hirano
Department of Hematology/Oncology, University of Tokyo, Japan.
In cynomolgus monkeys, twice daily subcutaneous injections of recombinant
human interleukin-6 (rhIL-6) at doses of 5 to 80 micrograms/kg/d for 14
consecutive days caused dose-dependent increases in platelet count, usually
continuing for more than 1 week after cessation of the injections. The
count reached a level approximately twofold or more above the preinjection
level even at 5 micrograms/kg/d, and at doses of more than 20
micrograms/kg/d, the increase became biphasic with a higher second peak 3
days after cessation of the injections. Morphologic analysis of the bone
marrow after the 7 day- injections with 80 micrograms/kg/d revealed a
marked increment in size of megakaryocytes compared with control,
indicating the promotion of megakaryocyte maturation. Other changes
attributable to the rhIL-6 treatment include dose-dependent loss of body
weight, anemia, neutrophilia and monocytosis, elevation of serum C-reactive
protein and alpha-1 acid glycoprotein levels, and decrease of serum
albumin; all of which returned to normal within 1 week after cessation of
the injections and were tolerable at doses of less than 10 micrograms/kg/d.
These findings suggest that rhIL-6 may be an effective strategy for the
treatment of thrombocytopenia.
Volume 75,
Issue 8,
pp. 1602-1605,
04/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Kagari, H. Doi, and T. Shimozato
The Importance of IL-1{beta} and TNF-{alpha}, and the Noninvolvement of IL-6, in the Development of Monoclonal Antibody-Induced Arthritis
J. Immunol.,
August 1, 2002;
169(3):
1459 - 1466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kaser, G. Brandacher, W. Steurer, S. Kaser, F. A. Offner, H. Zoller, I. Theurl, W. Widder, C. Molnar, O. Ludwiczek, et al.
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis
Blood,
November 1, 2001;
98(9):
2720 - 2725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hulkkonen, M. Pertovaara, J. Antonen, A. Pasternack, and M. Hurme
Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the disease
Rheumatology,
June 1, 2001;
40(6):
656 - 661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-J. Schuringa, A. T. J. Wierenga, W. Kruijer, and E. Vellenga
Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6
Blood,
June 15, 2000;
95(12):
3765 - 3770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Sui, K. Tsuji, Y. Ebihara, R. Tanaka, K. Muraoka, M. Yoshida, K. Yamada, K. Yasukawa, T. Taga, T. Kishimoto, et al.
Soluble Interleukin-6 (IL-6) Receptor With IL-6 Stimulates Megakaryopoiesis From Human CD34+ Cells Through Glycoprotein (gp)130 Signaling
Blood,
April 15, 1999;
93(8):
2525 - 2532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. O'Malley, P. Langhorne, R.A. Elton, and C. Stewart
Platelet Size in Stroke Patients
Stroke,
June 1, 1995;
26(6):
995 - 999.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. D. Anderson
Cytokine-Induced Changes in the Leukon
Toxicol Pathol,
January 1, 1993;
21(2):
147 - 157.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T Kishimoto, S Akira, and T Taga
Interleukin-6 and its receptor: a paradigm for cytokines
Science,
October 23, 1992;
258(5082):
593 - 597.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Nakahama, M. Okada, M. Miyazaki, N. Imai, T. Yokokawa, and S. Kubori
Distinct Responses of Interleukin-6 and Other Laboratory Parameters to Treatment in a Patient with Polyarteritis Nodosa A Case Report
Angiology,
June 1, 1992;
43(6):
512 - 516.
[Abstract]
[PDF]
|
|
|
|
|
